18 November 2024
The Malaghan Institute recently partnered with Zephyr Consulting Limited to help support future leaders in ground-breaking cancer therapies.
Inspired by our ground-breaking cancer research and its potential to enhance the health and wellbeing of our community, Zephyr are passionate about supporting emerging scientific talent. As a result, they have generously committed to fund Malaghan PhD student Paul Owaci’s tuition for three years.
Paul is working within the CAR T team investigating ‘exhaustion’ of CAR T-cells – a phenomena that could be why some people’s lymphomas do not respond to, or relapse after, CAR T-cell therapy. He is exploring alternative CAR T-cell manufacturing processes that could help reduce exhaustion, and to re-engineer CAR T-cells to knock down genes linked to this exhaustion.
At the Malaghan, we recruit top PhD students from New Zealand and abroad, whose passion, skill and international connections fuel scientific discovery.
As a charity, the support of these individuals comes largely through university scholarships – often needing additional funds from the community to cover things like living expenses. Through support like Zephyr’s, these future scientific world-leaders have the right support and tools needed to make the most out of their doctoral studies, setting them on the best path for a long and fruitful scientific career.
We are immensely grateful to Zephyr for their valued partnership and their commitment to empowering the next generation of scientific leaders. If you would like to learn more about how you can drive impact by supporting life-changing medical research with the Malaghan, please email us at [email protected] to discuss ways to partner with us.
Related articles
In Focus: CAR T-cell therapy, the battle of the blood cells
26 September 2024
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
CAR T-cells approved by EPA for phase 2 trial
23 May 2024
A revolution in cancer care is near; here’s what’s needed to make it happen
9 May 2024
Significant milestone reached in first NZ CAR T-cell trial as preparations made for larger phase 2 registration trial
25 March 2024
Freemasons New Zealand renews support for CAR T-cell therapy
10 November 2023